Rare Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your tumor has been tested by a lab and found to have a specific genetic change called a BRAF V600E mutation
- You have at least one tumor that can be measured on a scan, according to standard medical guidelines
- You have not previously been treated with the drugs dabrafenib and/or trametinib, OR you took these drugs for a different cancer but stopped taking them more than 1 year ago
- You are able to provide your scan images for review by a central medical team
Who may not be able to join:
- You have one of the following cancer types: melanoma, non-small cell lung cancer, anaplastic thyroid cancer, bile tract cancer, glioma, or colorectal cancer (confirm with trial site if you are unsure which category your cancer falls into)
- You have a medical reason why you should not take dabrafenib and/or trametinib, based on official guidelines in your country
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.